Table 3.

Clinical relevance of rs2232618 among trauma patients in the two cohorts

	Genotypes	N	Age (years)	Sex (M/F, %)	ISS	Sepsis, n (%)	MOD score
Southwest	TT	1166	42.6 ± 12.8	81.4/18.6	20.8 ± 9.3	373 (32.0)	6.11 ± 2.24
	TC	123	41.7 ± 13.9	77.2/22.8	25.0 ± 9.7	54 (43.9)	7.20 ± 2.23
	CC	7	43.0 ± 10.7	100/0	24.1 ± 13.2	5 (71.4)	8.17 ± 3.19
						a1, b1, c1	a2
Southeast	TT	388	41.3 ± 12.2	78.1/21.9	21.5 ± 9.3	136 (35.1)	5.88 ± 2.32
	TC	54	42.1 ± 12.9	79.6/20.4	23.4 ± 9.3	29 (53.7)	7.39 ± 3.73
	CC	3	32.7 ± 8.1	33.3/66.7	21.3 ± 7.2	2 (66.7)	6.00 ± 1.41
						a3, c2	a4
Total	TT	1554	42.3 ± 12.6	80.6/19.4	21.0 ± 9.3	509 (33.0)	6.07 ± 2.24
	TC	177	41.2 ± 13.7	92.1/7.9	22.5 ± 10.3	83 (46.9)	7.27 ± 2.87
	CC	10	43.4 ± 12.1	80.0/20.0	23.8 ± 11.9	7 (70.0)	8.00 ± 2.94
						a5, b2, c3	a6

Dominant effect (variant homozygotes + heterozygotes vs. wild homozygotes) as analyzed by ANCOVA: ^a1P = 0.002, ^a2P = 1.8E−6, ^a3P = 0.002, ^a4P = 0.005,^a5P = 4.5 × 10⁻⁴, ^a6P = 1.4E−9

Recessive effect (variant homozygotes vs. heterozygotes + wild homozygotes) as analyzed by ANCOVA: ^b1P = 0.032, ^b2P = 0.041

Allele dose association by logistic regression: ^c1P = 0.001(OR = 1.77, 95% CI = 1.26–2.48), ^c2P = 0.006(OR = 2.11, 95% CI = 1.24–3.58), ^c3P = 0.005(OR = 1.54, 95% CI = 1.34–2.08)